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Erythropoietin stimulates proliferation of human renal carci- tion in a stage-specific manner [reviewed in 2, 3]. Al-
noma cells. though the in vivo functions of EPO-Rs in the kidney
Background. We reported recently that normal human, rat, have yet to be determined, our recent observations sug-and mouse tubular cells express authentic erythropoietin-recep-
gest that EPO may act as a cytokine in renal cells.tors (EPO-R) through which EPO stimulates mitogenesis. The
Most types of human renal-cell carcinomas (RCCs)present study examines whether EPO could elicit such a prolif-
erative and thereby potentially detrimental response in cells are derived from proximal tubular cells [4, 5], which carry
of human renal-cell carcinoma (RCC). functional EPO-Rs [1]. If mitogenically active EPO-Rs
Methods. Nephrectomy samples were screened from patients continue to be expressed in malignantly transformedwith RCC (one chromophilic, two clear cell) as well as cell lines
proximal tubular cells, endogenous or administered EPOof human (Caki-2, 786-0) and mouse (RAG) renal adenocarci-
could hasten tumor growth. Possible detrimental effectsnomas for expression of EPO-R transcripts and protein. Cells
were further tested for specific 125I-EPO binding and mitogenic of EPO on tumor growth may be further mediated by
response to EPO. its known angiogenic activity [6–10]. Renal cell carcino-
Results. Authentic EPO-R transcripts and protein (approxi-
mas are commonly hypervascular, and experimental inter-mately 72 kD) were detected in renal tumors and cell lines.
ventions that enhance or inhibit angiogenesis are known toTumors showed low-level EPO expression, while cell lines did
not. In cells, specific 125I-EPO binding to a single class of EPO-R accelerate or retard tumor growth, respectively [11, 12].
(apparent Kd 1.3 to 1.4 nmol/L, Bmax 2.2 to 2.6 fmol/mg protein) In general, only 5% or less of patients with RCC de-
was observed. EPO stimulated cell proliferation dose depen- velop polycythemia caused by paraneoplastic overproduc-
dently, and the individual mitogenic effects of either EPO or
tion of EPO, while approximately 35% develop significant10% newborn calf serum were markedly amplified when both
anemia [13, 14], which may be treated with recombinantwere coadministered.
Conclusion. These data are the first to demonstrate, to our EPO. Physiological EPO production is stimulated by
knowledge, that human RCCs express EPO-R message and tissue hypoxia and occurs primarily in peritubular fibro-
protein and that receptor activation stimulates their prolifera- blasts situated in the renal cortical labyrinth [2, 15–17].tion in vitro. If these mitogenic effects of EPO are also opera-
Rare clinical cases of EPO-secreting RCCs, composedtive in patients with RCC, endogenous EPO or its administration
of malignantly transformed proximal tubular cells, havefor the treatment of anemia could potentially hasten prolifera-
tion of renocellular malignancies. been described [18–24]; their cells, when grafted into
athymic nude mice, are tumorigenic and produce polycy-
themia caused by constitutive EPO secretion. Activation
Recently, we reported that all regions of normal hu- of renal EPO-Rs might thus occur in RCCs by both
man, rat, and mouse kidney, as well as glomerular mesan- endocrine and paracrine pathways. Furthermore, the
gial, proximal tubular, and medullary collecting duct cells coexpression of EPO and its receptor in the same cell
express authentic erythropoietin receptors (EPO-R) could allow autocrine stimulation and could potentially
whose activation stimulates cell proliferation in vitro [1]. lead, as seen in some hematological malignancies, to
In erythroid progenitor cells, EPO stimulates cell prolif- autocrine transformation [25].
eration, inhibits apoptosis, and induces cell differentia- The prognostic significance of increased EPO produc-
tion in patients with RCC is unclear. Janik et al first
suggested that increased EPO production by RCCs mayKey words: von Hippel-Lindau disease, angiogenesis, proliferating
cells, anemia, tumor malignancy. mark interleukin-2 (IL-2)/a-interferon (IFN)–responsive
tumors [26]; they reported that IL-2/a-IFN therapy re-Received for publication September 22, 1999
sulted in significant responses in five patients with meta-and in revised form February 4, 2000
Accepted for publication March 13, 2000 static RCC and polycythemia. They concluded, however,
that in a larger series of patients, only 15% of those withÓ 2000 by the International Society of Nephrology
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polycythemia responded to this therapy, the same re- in vivo, we suggest that treatment of RCC patients with
EPO should be carried out with some degree of caution.sponse rate obtained in nonpolycythemic RCC patients,
and furthermore, all five patients who responded initially
suffered subsequent relapses and metastatic disease. A
METHODS
later in vitro study suggested that EPO-producing cells
Human kidney tissue and cell lines of renal carcinomaof RCC exhibited higher susceptibility to lysis by LAK
cells [27]. In a subsequent study, Ljungberg, Rasmuson, Nephrectomy specimens from three male patients (ages
54, 61, and 62) with confirmed RCC were obtained intra-and Grankvist suggested that increased serum EPO lev-
els in the absence of polycythemia, observed in a surpris- operatively with Internal Review Board (IRB) approval.
Anatomical localization of tumors within the kidney wasingly high 33% of their 165 patients, carried a worse
prognosis and indicated a higher incidence of progressive determined, and the tumor and adjacent normal-ap-
pearing tissues were immediately placed into chilledmetastatic disease [28]. On the other hand, a prospective
study on 49 patients with RCC found essentially no evi- phosphate-buffered saline (PBS), rinsed free of blood,
and frozen in liquid nitrogen or fixated (10% formalde-dence for paraneoplastic EPO overproduction, and also
failed to detect EPO expression in various established hyde) for histologic examination as reported [33]. Tissue
samples were stored at 2708C until RNA was extracted.cell lines of human RCC [29].
The impact of administered EPO on the growth of Representative portions of the renal tumors and adjacent
normal kidney tissues were processed for histologic ex-RCC is also uncertain. A case report on a single patient
with metastatic RCC suggested that high doses of EPO amination, paraffin embedded, sectioned, and stained
with periodic acid-Schiff stain. Tumor histology was re-caused a complete remission of all lesions [30]. In a later
study of 20 such patients given similar EPO treatment, corded photographically.
Two established human renal carcinoma cell lines,one achieved complete remission. Thirteen showed par-
tial or minor responses, and the remaining six were unaf- Caki-2 and 786-0, were examined (ATTC, Rockville, MD,
USA). Both are derived from human renal adenocarci-fected [31]. Since publication of these reports, no rigor-
ously controlled studies have confirmed the suggested nomas. Caki-2 cells have no mutation of the von Hippel-
Lindau (VHL) tumor suppressor gene, while 786-0 cellspositive effects of EPO in patients with RCC. The obser-
vation, finally, that EPO administration in an anemic do [34]. In addition, a murine renal adenocarcinoma cell
line, RAG, derived from BALB/cd strain of mice waspatient with multiple myeloma may have caused further
malignant transformation resulting in plasma cell leuke- studied (ATTC). Caki-2 cells were grown in McCoy’s
5a medium and 10% newborn calf serum (NCS; Hyclone,mia called into question the safety of EPO treatment
for patients with EPO-R expressing myeloma cells [32]. Logan, UT, USA), 786-0 cells in RPMI 1640 and 10%
NCS, and RAG cells in Dulbecco’s modified Eagle’sThus, considered together, the available data are unable
to yield conclusive evidence regarding the prognostic medium (DMEM) and 10% NCS. All cultures were incu-
bated at 378C in 5% CO2/air and grown to high subcon-significance of (1) EPO production by RCCs and (2)
their response to EPO administration. fluence.
As controls, normal human proximal tubular cellsAdvanced stages of RCC continue to carry a poor
prognosis and are often associated with EPO-responsive (HCT; Clonetics Corp., San Diego, CA, USA) at passage
2 were grown to high subconfluence in a 1:1 mixture ofanemia [11, 14]. EPO acts, as we demonstrated [1], as a
mitogen in normal renal cells. It stimulates proliferation Dulbecco’s modified Eagle’s medium and F12 containing
1 3 ITS (insulin, transferrin, selenium; Sigma, St. Louis,and migration of vascular endothelial cells [9, 10], and
it augments angiogenesis [6–8]. Because these cellular MO, USA), epidermal growth factor (EGF; 10 ng/mL),
T3 (4 pg/mL) and 10% NCS at 378C in 5% CO2/air.responses to EPO may collectively promote tumor growth
and because these actions may be enhanced further by
mRNA isolation, reverse transcription-polymerasehigh endogenous EPO production or by EPO adminis-
chain reaction, and gel electrophoresistration, in the present study we examined (1) whether
RCC and malignant renal tubular cell lines express EPO-R Total RNA was isolated from tissues and cultured cells
by an acid guanidinium-thiocyanate-phenol-chloroformand (2) whether receptor activation stimulates their pro-
liferation. method [35], using TRI Reagent (Molecular Research
Center, Inc., Cincinnati, OH, USA). For the reverse tran-We found intense expression of EPO-R message and
protein in human renal cell carcinoma and in established scription-polymerase chain reaction (RT-PCR) reactions,
1 mg of total mRNA was reverse transcribed (M-MLVcell lines of renal cancer. Activation of the EPO-R stimu-
lated cell proliferation in vitro. These observations are reverse transcriptase; GIBCO, Grand Island, NY, USA),
and the resulting cDNAs were subjected to 35 cycles ofcompatible with the notion that EPO administration to
patients with RCC could accelerate tumor growth. Until the PCR. Amplification of the examined cDNAs was
linear up to 35 PCR cycles for all primer sets used init is demonstrated that EPO lacks such trophic effects
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Fig. 1. Schema of the mRNA that encodes
the erythropoietin receptor (EPO-R) [36, 38].
It is composed of eight exons; exons I through
V represent the exoplasmic domain (N-termi-
nus), exon VI, the single transmembrane do-
main, and exons VII and VIII, the cytoplasmic
domain (C-terminus). Regions of the human
EPO-R that are bound by the three polymerase
chain reaction (PCR) primers (1 through 3)
and the size of the obtained PCR products are
indicated (not to scale).
this study. For human samples, three sets of PCR primers linear Scatchard [41] and nonlinear (GraphPad Software,
Inc., San Diego, CA, USA) regression analyses of thewere chosen, each specific to a different domain of hu-
man EPO-R cDNA (Fig. 1). Their individual sequences equilibrium-binding data were performed. The time
course of ligand binding was determined by incubatingand respective positions within the coding sequence are
as previously reported [1, 36]. 125I-rhEPO at a concentration of 620 pmol/L with approx-
imately 1 3 106 cells at 158C for four hours. To testFor mouse EPO-R cDNAs, two sets of primers were
used for PCR amplification of homologous sequences as whether specific EPO binding has a linear correlation
with the number of cells used, increasing numbers ofpreviously reported [1, 37, 38].
For the detection of human EPO mRNA, the follow- cells from 0 to 9 3 106 were incubated with 125I-rhEPO
(620 pmol/L) for three hours at 158C both in the absenceing set of PCR primers was used [39]: sense, 24-mer, 59
position 335, 59-ATC ACG ACG GGC TGT GCT GAA and the presence of 200-fold excess unlabeled EPO.
CAC-39, and antisense, 24-mer, 39 position 600, 59-GGG
Immunological detection of erythropoietinAGA TGG CTT CCT TCT GGG CTC-39, yielding a
receptor protein289 bp PCR product containing exons II through V.
As internal controls, human and mouse b-actin mRNAs Freshly resected tumor and adjacent normal tissue
derived from the same kidney tissues and cultured cells and cultured Caki-2 and 786-0 cells were examined. The
were identically reverse transcribed and PCR amplified. latter were grown to high subconfluence in 75 cm2 tissue
The primers used for human b-actin cDNA were as pre- culture flasks, washed twice with ice-cold PBS, and col-
viously reported [1], yielding a 279 bp product. All lected by scraping and centrifuging. The pellet was frozen
primer pairs for EPO-R and EPO cDNA were chosen at 2708C. Cell membrane protein extracts from kidney
to span introns (Fig. 1), thus facilitating control for con- tissues and cells were prepared as previously reported
tamination by genomic DNA. All cell and tissue extracts [1, 42]. These were then mixed 1:1 with 40 mL 2 3
were subjected to the PCR reaction once with and once Laemmli’s sample buffer and heated at 1008C for four
without initial reverse transcription. minutes prior to electrophoresis on 9% sodium dodecyl
All PCR products were size fractionated on 2.5% Nu- sulfate (SDS)-polyacrylamide gel, as previously reported
Sieve agarose and 1% agarose gel (FMC Bioproducts, [43, 44]. The separated protein bands were then electro-
Rockland, ME, USA), stained with ethidium bromide, phoretically transferred to Hybond-P membrane (Amer-
and band locations were recorded by photographing sham). A 1:1000 dilution of the primary antibody (affinity
them under ultraviolet light. Size standards of DNA were purified, polyclonal rabbit anti–EPO-R antibody, spe-
run in parallel (pBR322 DNA MSP I digest; New En- cific for human or mouse and rat; Santa Cruz Biotechnol-
gland Bio Labs, Beverly, MA, USA). ogy, Santa Cruz, CA, USA) in blocking buffer was then
added. Preparations were further incubated, and after
Specific erythropoietin binding to cells three washes in TBS-T, the second antibody was added
(1:1000 dilution of an horseradish peroxidase-conjugatedCells were grown to subconfluence, as described pre-
viously in this article, and mechanically harvested. They anti-rabbit IgG; Santa Cruz Biotechnology), followed by
a one-hour incubation at room temperature. After fourwere then washed at 48C for three minutes with 0.5 mol/L
NaCl and 0.25 mol/L acetic acid, pH 2.5, in order to remove washes in TBS-T, the protein bands were made visible,
using the enhanced chemiluminescence detection methodEPO bound to the cell surface [40] and washed twice more
with PBS, pH 7.3. Binding assays, using 125I-rhEPO (specific (ECL; Amersham), and recorded on radiographic film
as previously reported [1, 43].activity 948 Ci/mmol; Amersham, Arlington Heights, IL,
USA) and unlabeled human EPO (recombinant human In addition, HeLa (ATTC) and HCD-52 cells were
used as negative and positive EPO-R–expressing con-EPO; Amgen, Royal Oaks, CA, USA) were carried out
as previously reported [1]. To obtain Kd and Bmax, both trols, respectively [1]. Western blots from the latter were
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generated, following prior immunoprecipitation, as pre- linear Scatchard [41] and nonlinear (GraphPad Software,
Inc., San Diego, CA, USA) regression analyses of theviously reported [1].
The specificity of anti–EPO-R antibody binding by equilibrium-binding data.
tumor and cell membrane protein extracts was further
assessed by reacting the primary blots, prepared as de-
RESULTS
scribed previously in this article, with a 1:1000 dilution
EPO receptor and EPO expression in human renalof primary antibody that had been neutralized (17 hours
cell carcinomaat 48C) with a 10-fold (by mass) excess of EPO-R antigen
(C-terminal peptide; Santa Cruz Biotechnology). The Figure 2 shows the histology of a renal carcinoma
resected from one of the three adult patients whose renalremaining steps of the immunodetection protocol were
then performed as described previously in this article. tumors were screened for EPO-R expression (discussed
in the Methods section). This cortical tumor is of the
Erythropoietin secretion granular or chromophilic cell type with solid growth pat-
tern, high vascularity, and of nuclear grade 3 [46, 47].Erythropoietin secretion by logarithmically growing
(at 24, 48, and 72 hours) and from quiescent Caki-2 and The other two tumors were of the clear-cell type. The two
clear-cell adenocarcinomas contained occasional small786-0 cells (after 24 hours in serum-free media) was de-
termined using a commercial enzyme-linked immuno- cysts and were also highly vascularized.
Figure 3 shows ethidium bromide-stained agarose gelssorbert assay (ELISA) (ALPCO, Windham, NH, USA).
The utilized batches of 10% NCS (Hyclone, Logan, UT, of EPO-R PCR products obtained from the tumor shown
in Figure 2. The bands in lanes 3, 4, and 5 represent theUSA) were also tested for EPO levels. The lower detec-
tion limit for this EPO assay is 10 mU/mL. expected 104, 372, and 240 bp PCR products of the hu-
man EPO-R cDNA (Fig. 1). The first lane shows DNA
Cell proliferation size standards and lane 2 the 249 bp b-actin PCR product,
used as internal control. The EPO-R PCR products de-All tested cell lines were seeded at 1 3 104/well in 96-
well plates and allowed to attach overnight in appro- rived from the other two tumor specimens and from adja-
cent normal renal tissue, as we previously reported [1],priate serum-containing media. Cells were rendered qui-
escent by incubation in serum-free media for 24 hours. were indistinguishable from those depicted in Figure 3.
Both the renal carcinomas and normal renal corticalRecombinant human EPO alone, at incremental concen-
trations, or NCS (10%) alone or in combination with tissue showed only a low-level EPO message. All three
patients were anemic at the time of diagnosis (meanvarious EPO doses, was then added, and the incubation
was continued for 24 or 48 hours as previously reported HCT 32 6 2%), and none of the patients were polycythe-
mic during the year preceding the resection of their tu-[1]. At these times, media were removed and replaced
with fresh media (without phenol red and serum) con- mors.
taining 5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
EPO receptor and EPO transcripts in malignantnyltetrazolium bromide (MTT; Thiazolyl blue; Sigma)
renal cellsand incubated at 378C for an additional three hours.
After this, the media were removed, and 100 mL of 0.04 To determine further whether malignant renal epithe-
lial cells express EPO-R mRNA, two defined cell linesN HCl in isopropanol were added to each well in order
to solubilize the blue MTT reduction product formed in that are derived from human RCCs were examined. This
was important since the EPO-R transcripts that wereviable cells. The absorbance was read on a microplate
reader at 570 nm with background subtraction at 650 found in renal tumor tissue could be expressed, as we
demonstrated recently [1], by nonepithelial cells such asnm. In addition, cell proliferation was assessed by hemo-
cytometer counting of trypsinized cells. There was excel- glomerular mesangial cells or by vascular endothelial or
intravascular erythroid progenitor cells. EPO-R expres-lent linear correlation (r 5 0.99) between cell counts and
results obtained by the MTT assay. sion in the murine RCC cell line RAG was also examined.
Figures 4 and 5 show ethidium bromide-stained aga-
Data reporting and statistical analysis rose gels of EPO-R PCR products obtained from Caki-2
and 786-0 cells, respectively. The bands in lanes 4, 5, andAll data on human renal tumors and individual cell
lines are representative of at least three to six replications 6 in both figures represent the expected 104, 372, and
240 bp PCR products of the human EPO-R cDNA (Fig.or independent experiments, respectively. Data are re-
ported as means 6 SE. Differences between data means 1) generated from Caki-2 and 786-0 cells, respectively.
The first lanes show DNA size standards and lanes 2 thewere analyzed for statistical significance (P , 0.05) using
Student’s t-test for paired and independent populations 249 bp b-actin PCR product, used as internal control.
In lane 3, the reverse transcriptase step was omitted, andas well as analysis of variance [45]. Apparent Kd and
Bmax values for 125I-EPO binding were derived by both no PCR products were detected. Neither Caki-2 nor 786-0
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Fig. 2. Histology of human renal cell carcinoma. Granular or chromophilic cell type, vascular tumor of nuclear grade 3 [46, 47]. Original magnification
3250, periodic acid-Schiff stain.
cells expressed EPO mRNA. In RAG cells, EPO-R
mRNA was detected in a pattern indistinguishable from
that obtained in non-neoplastic murine proximal tubular
cells (data not shown) [1]. None of the cell lines secreted
detectable amounts of EPO into the media.
Specific EPO binding to cell surface and immunologic
detection of EPO-R protein
In human renal cancer cells, Caki-2, and normal HCTs,
as well as in murine RAG cells, specific binding of
125I-EPO to cell surface EPO-R was examined. Specific
binding of 125I-EPO in all cell lines occurred to a single
class of receptors with intermediate affinity (Caki-2, ap-
parent Kd 1.4 6 0.2 nmol/L, Bmax 2.2 6 0.3 fmol/mg
Fig. 3. EPO-R transcripts of human renal cell carcinoma. Ethidium protein, N 5 3; HCT, apparent Kd 1.1 6 0.1 nmol/L, Bmaxbromide-stained gel shows in lane 3 the expected 104 bp EPO-R PCR
1.6 6 0.2 fmol/mg, N 5 3; RAG cells, apparent Kd 1.3 6product (1. primer set in Fig. 1), in lane 4 the 372 bp (3. primer set),
and in lane 5 the 240 bp PCR (2. primer set) from the renal carcinoma 0.3 nmol/L and Bmax 2.6 6 0.2 fmol/mg, N 5 3), and
depicted in Figure 2. The first lane shows DNA size standards, and lane ligand binding became saturated within approximately 1.52 the 249 bp b-actin PCR product, used as internal control. The EPO-
hours. Nonlinear and Scatchard analyses yielded compa-R transcript patterns of adjacent normal renal cortex (1) and of the
other two RCCs, both of clear cell type, were identical to that depicted rable results. There was excellent linear correlation (r 5
here. EPO transcripts were detectable at low intensity in both normal
0.99) between specific ligand binding in tested cell linesand tumor tissues (data not shown).
and cell numbers. It is of note that specific binding of
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Fig. 4. EPO-R and EPO expression in Caki-2 malignant renal cells.
Ethidium bromide-stained gel shows in lanes 4, 5, and 6 the expected
EPO-R PCR products (104, 372, and 240 bp) as defined in Figure 1
and as detected in RCC (Fig. 3). Lane 1 shows DNA size standards.
Lane 2 shows the 249 bp b-actin PCR product, used as internal control,
and in lane 3, the reverse transcriptase step was omitted. Caki-2 cells
do not express EPO mRNA.
Fig. 6. Immunodetection of EPO-R protein in RCC, Caki-2, and 786-
0 cells. (A) Western blots for EPO-R protein were generated using
membrane protein extracts of resected tumor tissue, Caki-2, and 786-
0 cells. Lane 1 shows molecular weight standards, and lanes 2 (tumorFig. 5. EPO-R and EPO expression in 786-0 malignant renal cells.
tissue, Fig. 2), 3 (Caki-2), and 4 (786-0) depict immunoreactive EPO-Ethidium bromide-stained gel shows in lanes 4, 5, and 6 the expected
R protein bands with an approximate molecular mass of 72 kD, respec-EPO-R PCR products (104, 372, and 240 bp) as defined in Figure 1
tively. When anti–EPO-R antibodies were first neutralized with anand as detected in RCC (Fig. 3) and Caki-2 cells (Fig. 4). Lane 1 shows
excess of specific antigen (C-terminal EPO-R peptide; Methods), noDNA size standards. Lane 2 shows the 249 bp b-actin PCR product,
EPO-R–specific immunoreactivity was detected. (B) Control Westernused as internal control, and in lane 3, the reverse transcriptase step
blots generated following immunoprecipitation of cell membrane prepa-was omitted. Caki-2 cells do not express EPO mRNA.
rations from EPO-R negative HeLa cells (lane 1) and EPO-R–expressing
HCD-57 cells (lane 2). The latter express EPO-R protein with molecular
masses of 72 and 78 kD [48]. The 72 kD form is also found in RCC
cells (Fig. 6A). Lane 3 depicts molecular weight standards.125I-EPO in murine proximal tubular cells occurred with
significantly higher affinity (Kd approximately 96 pmol/L)
than in the cells examined here [1]. HCD-57 cells express functional EPO-R with molecular
masses of 72 and 78 kD. The predominant 72 kD formWestern blots for EPO-R protein were generated us-
ing membrane protein extracts of resected tumor tissue, is also present in RCC cells (Fig. 6A).
Caki-2 and 786-0 cells (Fig. 6A). Lane 1 on Figure 6A shows
Mitogenic action of EPO in malignant renal cellsmolecular weight standards, and lanes 2 (tumor tissue; Fig.
2), 3 (Caki-2) and 4 (786-0), depict immunoreactive Figure 7 A, C, and E demonstrate that EPO, dose
dependently and significantly, stimulates cell prolifera-EPO-R protein bands, all with an approximate molecular
mass of 72 kD. When anti–EPO-R antibodies were first tion in serum-deprived Caki-2, 786-0, and RAG cells.
The maximal proliferative response in 786-0 cells wasneutralized with an excess of specific antigen (C-terminal
EPO-R peptide; Methods section), no EPO-R–specific achieved with 1 to 5 U/mL of EPO, while progressively
higher EPO doses caused further proliferation of Caki-2immunoreactivity was detected. Figure 6B shows control
Western blots from EPO-R–negative HeLa cells, lane 1, cells. These responses were, as in normal renal cells, most
prominent at 48 hours following EPO administration [1].and from EPO-R expressing HCD-57 cells, lane 2. Lane 3
depicts molecular weight standards. As previously dem- Addition of 10% NCS to “quiescent” Caki-2 (Fig. 7B),
786-0 (Fig. 7D), and RAG (Fig. 7E) cells consistentlyonstrated by Sawyer and Hankins [48] and others [3],
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Fig. 7. Cell proliferation in response to EPO and NCS in malignant
renal cells. The proliferative response to EPO alone in quiescent Caki-2
(A), 786-0 (C), and RAG (E) cells is depicted. EPO (black bars) in-
creased cell numbers dose dependently and significantly (after 48 hours
of incubation). SFM, serum free media (open bars). *P , 0.05 compared
with quiescent control cells (open bar). Addition of 10% NCS (gray bar)
to quiescent Caki-2 (B) and 786-0 (D) cells stimulated cell proliferation
significantly (P , 0.05). The combination of EPO and 10% NCS in the
media caused a further dose-dependent increase in Caki-2 (B) and 786-
0 (D) cell proliferation. Because the EPO levels in the utilized NCS were
undetectable by EIA, we excluded the possibility that this synergistic
effect was caused by additional EPO contained in the calf serum.
stimulated cell proliferation by approximately 1.6- to 8- eration. The response patterns of both cell lines were
again similar to those obtained in serum-free media (Fig.fold (P , 0.05), and this response served as positive
control. Figure 7 B and D illustrate that the combination 7 A, C) in that the proliferative response of 786-0 cells
plateaued with 0.5 to 1 U/mL of EPO, while incrementalof EPO and 10% NCS in the media caused a further
dose-dependent increase in Caki-2 and 786-0 cell prolif- EPO doses led again to further increases in Caki-2 cell
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proliferation. Since the EPO levels in the utilized NCS hemopoietic cells [60], is not known. It is equally unex-
plored whether the high proliferative index found inwere undetectable by EIA (,10 mU/mL), we excluded
the possibility that this additive effect was caused by RCCs is associated with an analogous increase in EPO-R
expression that results in magnified responsiveness toadditional EPO contained in the calf serum.
EPO and thus proliferation of tumor cells, and it is also
unclear whether the very low proliferative index of nor-
DISCUSSION
mal tubular cells is associated with decreased EPO-R
Our data demonstrate clearly that human RCC tissue expression [1], which, in turn, could explain why normal
and cell lines both express authentic EPO-R mRNA and kidneys are largely unresponsive to EPO in vivo.
protein. The expression intensity, although not specifi- Since activating mutations of the EPO-R were found
cally quantitated, resembles that seen in normal kidney to cause transformation of hematopoietic cells [61], the
or control proximal tubular cells [1]. While specific EPO question arises whether this also occurs in RCCs. And
binding to the cell surface EPO-R occurs with somewhat finally, pathologically elaborated EPO in RCCs may con-
lower affinities in both the malignant and the primary ceivably be mutated, as was shown in hepatoma cells
HCT cell lines than in erythroid progenitor or mouse [62], which may also cause changes in ligand-binding
proximal tubular cells (Kd , 1.1 to 1.6 nmol/L vs. , 96 kinetics and thus alter postreceptor events.
pmol/L, respectively) [1], maximal ligand binding, Bmax, Anagnostou et al demonstrated previously that EPO
in malignant and normal human cells is greater. EPO stimulates proliferation and migration of vascular endo-
alone stimulates cell proliferation of quiescent Caki-2, thelial cells [9, 10], and Carlini, Reyes, and Rothstein
786-0, and RAG cells; the mitogenic response in the [6] and Yasuda et al [8] showed that EPO augments
human cell lines is amplified when EPO is combined with angiogenesis in vitro and in vivo, respectively. It has
10% NCS. Undetectable EPO levels in the utilized calf also been demonstrated that normal renal vessels and
serum indicate that this additive effect must result from mesangial cells express vasoactive EPO-R [42]. This im-
synergism between EPO and other growth factors or cyto- plies that endothelial cells of renal tumor vessels likewise
kines that are contained in NCS. Potential candidates for express EPO-Rs through which EPO could stimulate
this synergism with EPO are insulin, insulin-like growth angiogenesis and thus advance tumor growth. The cen-
factor-I, EGF, transforming growth factor-a (TGF-a), tral role of angiogenic factors in progression of RCC is
TGF-b, hepatocyte growth factor, platelet-derived growth well recognized. More than 70% of patients with spo-
factor, basic fibroblast growth factor, IL-6, and probably radic clear cell carcinoma show inactivating mutations
others [14, 49–56]. Receptors for most of these have of the VHL gene [11, 14], whose wild-type gene product
been identified in cell lines derived from RCCs, including acts to suppress tumor growth through negative control
Caki-2 and 786-0 cells, and their respective activation of angiogenic factors such as vascular endothelial growth
was shown to stimulate or modify cell proliferation. factor, TGF-a, and TGF-b [34]. Whether EPO, via its
Damen et al reported recently that hyper-respon- angiogenic activity, can play an analogous role in the
siveness to EPO in murine hemopoietic cells that express growth of RCCs awaits examination.
C-terminally truncated EPO-Rs is only obtained when Taken together, it remains to be investigated which
cells are incubated with fetal calf serum that is known of the hypothetical mechanisms considered previously
to contain IGF-I [57]. Since IGF-I has an EPO-sparing in this article actually apply to the observed responses
effect in patients with anemia of chronic renal failure elicited by EPO and NCS in the present in vitro study.
[58] and since it is a renotropic mitogen [59], we searched Despite these unanswered questions, our data suggest
for but were unable to demonstrate such synergism be- that EPO possesses the potential to alter the growth of
tween EPO and IGF-I in cultured tubular cells (unpub- those RCCs whose neoplastic epithelial and vascular
lished preliminary data). Although we did not specifically cells express functional EPO-Rs.
search for C-terminal truncations of the EPO-R, we The 786-0 cell line, unlike Caki-2 cells, lacks the wild-
found, using the third primer set as defined in Figure 1, type VHL tumor suppressor gene [34]. Although the
a largely intact C-terminal domain that encodes, in part, EPO-R expression patterns in both cell lines were similar
a negative growth-regulatory site [3]. Truncations, how- (Figs. 4–6), their mitogenic responses to EPO and NCS
ever, that include the C-terminus itself, and immediately were different (Fig. 7). In 786-0 cells, relatively low doses
adjacent sequences would not have been detected by of EPO (0.5 to 1.0 U/mL), both in serum-free media
our analysis. Accordingly, C-terminal EPO-R trunca- and in combination with 10% NCS, elicited maximal,
tions that may contribute to the observed synergistic although modest cell proliferation. In contrast, Caki-2
effects of EPO and serum cannot be entirely ruled out. cells responded with further increases in proliferation to
Whether the serum-induced increase in cellular respon- progressively higher doses of EPO. An explanation for
siveness to EPO could result from amplification of EPO-R these differences in growth response is not currently
available. It is furthermore unknown whether the pres-expression, as occurs in serum-stimulated transformed
Westenfelder and Baranowski: EPO and renal cell carcinoma 655
ence or lack of wild-type VHL protein has any direct in the other three [66]. None of our patients presented
with polycythemia, and EPO levels were not determined.bearing on EPO-R expression and activation. It is of note
in this context that the lack of the VHL gene product, a Although it was suggested that EPO expression by RCC
cells may indicate heightened responsiveness to IL-2/tumor suppressor, leads in patients with RCC to en-
hanced proliferative and angiogenic activity. The growth a-IFN therapy [26], this impression was not confirmed
when larger numbers of patients were evaluated.response pattern of Caki-2 cells is compatible with main-
tained or up-regulated EPO-R expression, while that In conclusion, our present data do not support the
notion that high ambient EPO levels have a curativeof 786-0 cells may reflect ligand-induced EPO-R down-
regulation. The possibilities have not been investigated. effect in RCC. Rather, our data provide significant initial
evidence to suggest that EPO administration to patientsOne larger clinical study of patients with RCC sug-
gested that elevated serum EPO levels signified a poor with RCC has the potential of modifying tumor growth
by stimulating cell proliferation and possibly angiogen-prognosis [28]. In vitro studies on two RCC-derived cell
lines showed neither a growth stimulatory nor an inhibi- esis. We suggest that these responses are mediated by
activation of EPO-Rs that are expressed in malignanttory effect of EPO [63]. Another study pertinent to this
question demonstrated that grafts of EPO-secreting renal tubular cells and that have not been described
previously. These observations in neoplastic tubular cellsRCC cells in athymic nude mice were less tumorigenic
than non-EPO–secreting cells [22]. The latter observa- also provide further insight into possible in vivo functions
of renal EPO receptors. We finally believe that our data,tion suggests that the secretion of EPO failed to increase
the aggressiveness of these tumors, arguing against the although obtained in vitro, should make clinicians aware
of the possibility that EPO administration may adverselypresence of an autocrine loop for EPO. On the other
hand, if EPO-Rs were absent or down-regulated, these affect patients with RCC. Conclusive evidence regarding
EPO’s potential significance as a tumor-promoting factortumors would obviously not be expected to respond to
EPO. It therefore follows that a complete understanding will, however, depend on the utilization of in vivo RCC
models and on rigorous outcome studies conducted inof these data will depend on whether or not EPO-secre-
ting RCC cells actually express functional EPO-R. RCC patients who are treated with EPO.
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